Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
← catalyst calendarNCT07290569 · readout ≤ 315 d
Sponsored by Oruka Therapeutics, Inc. (industry) · ORKA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
160estimated
Sites
36
Countries
Canada, Germany, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-03 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: ORKA-001
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving 100% Reduction in PASI Score at Week 16
measured Week 16
Permalink · ORKA's whole pipeline · Catalyst calendar · Every registered study · What changed